New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
09:20 EDTEWEdwards Lifesciences' SAPIEN XT valve approved in EU
Edwards Lifesciences announced it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery. Edwards is the only company to receive a valve-in-valve indication for the mitral position, which addresses an unmet need within the clinical community to provide an alternative to a high-risk surgery.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:58 EDTEWEdwards Lifesciences price target raised to $179 from $157 at Stifel
Subscribe for More Information
07:46 EDTEWEdwards Lifesciences price target raised to $178 from $160 at Canaccord
Subscribe for More Information
07:43 EDTEWEdwards Lifesciences price target raised to $185 from $155 at Leerink
Subscribe for More Information
07:23 EDTEWEdwards Lifesciences price target raised to $168 from $155 at JPMorgan
Subscribe for More Information
July 28, 2015
16:30 EDTEWEdwards Lifesciences sees Q3 EPS 92c-$1.00, consensus 98c
Sees Q3 revenue $580M-$620M, consensus $587.06M.
16:28 EDTEWEdwards Lifesciences raises FY15 EPS view to $4.30-44.40, consensus $4.28
Backs FY15 revenue view $2.3B-$2.5B, consensus $2.41B
16:26 EDTEWEdwards Lifesciences reports Q2 EPS $1.13 , consensus $1.05
Subscribe for More Information
15:21 EDTEWNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use